Ribon Therapeutics Overview

  • Founded
  • 2015
Founded
  • Status
  • Private
  • Employees
  • 47
Employees
  • Latest Deal Type
  • Series B
  • Latest Deal Amount
  • $65M
Latest Deal Amount
  • Investors
  • 10

Ribon Therapeutics General Information

Description

Developer of a biotech platform intended to block cancer cell's fundamental ability to survive under stress. The company's offerings include discovery and development of first-in-class small molecule inhibitors or each enzyme in the target family, enabling doctors to help treat patients suffering from cancer.

Contact Information

Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • 35 Cambridgepark Drive
  • Cambridge, MA 02140
  • United States
+1 (617) 000-0000

Ribon Therapeutics Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Ribon Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series B) 04-Jan-2019 $65M 00000 00000 Completed Clinical Trials - Phase 1
1. Early Stage VC (Series A) 10-Oct-2017 000.00 000.00 000.00 Completed Startup
To view Ribon Therapeutics’s complete valuation and funding history, request access »

Ribon Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series A 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
To view Ribon Therapeutics’s complete cap table history, request access »

Ribon Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of a biotech platform intended to block cancer cell's fundamental ability to survive under stress. The company
Biotechnology
Cambridge, MA
47 As of 2020
00000
0000 0000-00-00
00000000000 00000

0000000

consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat n
0000 000000000
Indianapolis, IN
0 As of 0000
000.00
00.00 0000-00-00
00000000000 000.00

0000000

t, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis
0000000000000
New York, NY
00 As of 0000
000.00
0000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Ribon Therapeutics Competitors (33)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Apexian Venture Capital-Backed Indianapolis, IN 0 000.00 00000000000 000.00
0000000 0000000000 Venture Capital-Backed New York, NY 00 000.00 0000000000 000.00
000000000 Venture Capital-Backed Gaithersburg, MD 00 000.00 00000000000 000.00
00000000 000000000 Venture Capital-Backed Uppsala, Sweden 00 0000000000
000000 00000000000 Corporation Plymouth Meeting, PA 000 000.00 00000000 000.00
You’re viewing 5 of 33 competitors. Get the full list »

Ribon Therapeutics Executive Team (10)

Name Title Board Seat Contact Info
Victoria Richon Ph.D President, Chief Executive Officer & Board Member
Paul Chang Ph.D Co-Founder & Scientific Advisor
Tim Mitchison Ph.D Co-Founder & Scientific Advisor
W. Kraus Ph.D Co-Founder & Scientific Advisor
Kevin Kuntz Ph.D Vice President, Molecular Discovery
You’re viewing 5 of 10 executive team members. Get the full list »

Ribon Therapeutics Board Members (10)

Name Representing Role Since
Anja König Ph.D Novartis Venture Fund Board Member 000 0000
Cameron Wheeler Ph.D Deerfield Management Board Member 000 0000
Emma Reeve Self Board Member 000 0000
James Audia Ph.D Self Board Member 000 0000
Jodie Morrison Self Chairman 000 0000
You’re viewing 5 of 10 board members. Get the full list »

Ribon Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ribon Therapeutics Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
AbbVie Ventures Corporate Venture Capital Minority 000 0000 000000 0
Celgene Corporation Minority 000 0000 000000 0
Johnson & Johnson Innovation - JJDC Corporate Venture Capital Minority 000 0000 000000 0
Novartis Venture Fund Corporate Venture Capital Minority 000 0000 000000 0
Deerfield Management Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 10 investors. Get the full list »